Stories

SaveSave story

U.S. biotech startups may IPO in Hong Kong

Illustration: Sarah Grillo, Axios

Hong Kong this week unveiled new stock exchange rules that will allow listings of unprofitable biotech companies, plus dual-class share structures.

Bottom line: The revised regs, which go into effect shortly, could attract some highly-valued U.S. biotech startups.